MET and cancer: in vitro studies showed that PTPN1 can mediate dephosphorylation of c‐Met and PIK3R2 by binding with both, thereby weakening cell proliferation, metastasis and erlotinib resistance, while CAPN1 could enhance the degradation of PTPN1 protein as a cancer promoter.